Is Brainstorm Cell Therapeutics Inc. (BCLI) a Buy, Sell, or Hold?
OTC : BCLI
Brainstorm Cell Therapeutics Inc.
$0.97 USD
$0.01 (1.04%)
- Volume
- 6.96K
- Average Volume
- 17.64K
- Market Capitalization
- $10.7M
- P/E Ratio
- -1.03
- Dividend Yield
- 0.00%
- Price Target
- Year High
- $1.69
- Year Low
- $0.46
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $0.02
NUMBER OF INSIDERS BUYING (LAST 12 MONTHS)
37
NUMBER OF INSIDERS SELLING (LAST 12 MONTHS)
2
AMOUNT OF INSIDER SELLING (LAST 12 MONTHS)
$63000
BCLI Estimated and Actual Revenue by Quarter
Get MSFT Insider Trade Alerts
BCLI Insider Trading History
| Insider Name | Title | Date | Transaction | Cost | Filing Date |
|---|---|---|---|---|---|
| Pitts Peter Joe | director | 2026-05-25 | 0.68 | 2026-06-03 | |
| Lebovits Chaim | officer: President & CEO | 2026-02-26 | A-Award | 0 | 2026-05-29 |
| Yablonka Uri | director, officer: EVP & Chief Business Officer | 2026-02-26 | A-Award | 0 | 2026-05-29 |
| Patlis Alla | officer: See Remarks | 2026-02-26 | A-Award | 0 | 2026-05-29 |
| FRENKEL JACOB A | director | 2026-02-26 | A-Award | 0 | 2026-05-29 |
| ARBEL IRIT | director | 2026-02-26 | A-Award | 0 | 2026-05-29 |
| Bairu Menghisteab | director | 2026-02-26 | A-Award | 0.7 | 2026-05-20 |
| Polverino Anthony J. | director | 2026-02-26 | A-Award | 0.7 | 2026-05-20 |
| HARTOUNIAN HARTOUN | director | 2026-02-26 | A-Award | 0.7 | 2026-05-20 |
| Lindborg Stacy | director | 2026-02-26 | A-Award | 0.7 | 2026-05-20 |
| Naor Nir | director | 2026-02-26 | A-Award | 0.7 | 2026-05-20 |
| Dagher Ibrahim B. | director | 2026-02-26 | A-Award | 0.7 | 2026-05-20 |
| Dagher Ibrahim B. | officer: Chief Medical Officer | 2025-01-01 | A-Award | 0 | 2025-01-07 |
| Dagher Ibrahim B. | officer: Chief Medical Officer | 2024-04-17 | 0 | 2025-01-07 | |
| Dagher Ibrahim B. | officer: Chief Medical Officer | 2024-04-17 | 0 | 2025-01-07 | |
| Dagher Ibrahim B. | officer: Chief Medical Officer | 2024-04-17 | 0 | 2025-01-07 | |
| Dagher Ibrahim B. | officer: Chief Medical Officer | 2024-04-17 | 1.73 | 2025-01-07 | |
| Lebovits Chaim | officer: President & CEO | 2025-01-01 | A-Award | 0 | 2025-01-03 |
| FRENKEL JACOB A | director | 2025-01-01 | A-Award | 0 | 2025-01-03 |
| Polverino Anthony J. | director | 2025-01-01 | A-Award | 0 | 2025-01-03 |
| Yablonka Uri | director, officer: EVP & Chief Business Officer | 2025-01-01 | A-Award | 0 | 2025-01-03 |
| Yablonka Uri | director, officer: EVP & Chief Business Officer | 2025-01-01 | A-Award | 0 | 2025-01-03 |
| Patlis Alla | officer: See Remarks | 2025-01-01 | A-Award | 0 | 2025-01-03 |
| Naor Nir | director | 2025-01-01 | A-Award | 0 | 2025-01-03 |
| Lindborg Stacy | director | 2025-01-01 | A-Award | 0 | 2025-01-03 |
| HARTOUNIAN HARTOUN | officer: EVP, Chief Operating Officer | 2025-01-01 | A-Award | 0 | 2025-01-03 |
| Bairu Menghisteab | director | 2025-01-01 | A-Award | 0 | 2025-01-03 |
| ARBEL IRIT | director | 2025-01-01 | A-Award | 0 | 2025-01-03 |
| Lebovits Chaim | officer: President & CEO | 2024-09-30 | P-Purchase | 0.228 | 2024-10-02 |
| Lebovits Chaim | officer: President & CEO | 2024-10-01 | P-Purchase | 3.4272 | 2024-10-02 |
| Lebovits Chaim | officer: President & CEO | 2024-05-28 | P-Purchase | 0.5183 | 2024-07-31 |
| Lebovits Chaim | officer: President & CEO | 2024-05-22 | P-Purchase | 0.64 | 2024-07-31 |
| Lebovits Chaim | officer: President & CEO | 2024-05-21 | P-Purchase | 0.579 | 2024-07-31 |
| Lebovits Chaim | officer: President & CEO | 2024-05-13 | P-Purchase | 0.49 | 2024-07-31 |
| Lebovits Chaim | officer: President & CEO | 2024-05-11 | P-Purchase | 0.4665 | 2024-07-31 |
| Lebovits Chaim | officer: President & CEO | 2024-05-10 | P-Purchase | 0.465 | 2024-07-31 |
| Lebovits Chaim | officer: President & CEO | 2024-05-07 | P-Purchase | 0.3743 | 2024-07-31 |
| Lebovits Chaim | officer: President & CEO | 2024-05-06 | P-Purchase | 0.3753 | 2024-07-31 |
| Lebovits Chaim | officer: President & CEO | 2024-04-19 | P-Purchase | 0.5199 | 2024-07-31 |
| Lebovits Chaim | officer: President & CEO | 2024-04-18 | P-Purchase | 0.5255 | 2024-07-31 |
| Lebovits Chaim | officer: President & CEO | 2024-04-17 | P-Purchase | 0.5457 | 2024-07-31 |
| Dagher Ibrahim B. | officer: Chief Medical Officer | 2024-07-19 | S-Sale | 0.3503 | 2024-07-24 |
| HARTOUNIAN HARTOUN | officer: EVP, Chief Operating Officer | 2024-06-24 | A-Award | 0.38 | 2024-06-25 |
| HARTOUNIAN HARTOUN | officer: EVP, Chief Operating Officer | 2024-06-24 | A-Award | 0 | 2024-06-25 |
| HARTOUNIAN HARTOUN | officer | 2024-06-24 | 0 | 2024-06-25 | |
| Lebovits Chaim | officer: President & CEO | 2024-05-28 | A-Award | 0.5183 | 2024-06-03 |
| Lebovits Chaim | officer: President & CEO | 2024-05-22 | A-Award | 0.64 | 2024-05-23 |
| Lebovits Chaim | officer: President & CEO | 2024-05-21 | A-Award | 0.579 | 2024-05-23 |
| Lebovits Chaim | officer: President & CEO | 2024-05-13 | A-Award | 0.49 | 2024-05-14 |
| Lebovits Chaim | officer: President & CEO | 2024-05-11 | A-Award | 0.4665 | 2024-05-14 |
| Lebovits Chaim | officer: President & CEO | 2024-05-10 | A-Award | 0.465 | 2024-05-14 |
| Lebovits Chaim | officer: President & CEO | 2024-05-07 | A-Award | 0.3743 | 2024-05-07 |
| Lebovits Chaim | officer: President & CEO | 2024-05-06 | A-Award | 0.3753 | 2024-05-07 |
| Lebovits Chaim | officer: President & CEO | 2024-04-19 | A-Award | 0.5199 | 2024-04-25 |
| Dagher Ibrahim B. | officer: Chief Medical Officer | 2024-04-17 | 0 | 2024-04-22 | |
| Dagher Ibrahim B. | officer: Chief Medical Officer | 2024-04-17 | 0 | 2024-04-22 | |
| Dagher Ibrahim B. | officer: Chief Medical Officer | 2024-04-17 | 0 | 2024-04-22 | |
| Lebovits Chaim | officer: President & CEO | 2024-04-18 | A-Award | 0.5255 | 2024-04-19 |
| Lebovits Chaim | officer: President & CEO | 2024-04-17 | A-Award | 0.5457 | 2024-04-19 |
| Lindborg Stacy | officer: Co-Chief Executive Officer | 2024-03-11 | A-Award | 0 | 2024-03-13 |
| Yablonka Uri | director, officer: EVP & Chief Business Officer | 2024-03-11 | A-Award | 0 | 2024-03-13 |
| Patlis Alla | officer: See Remarks | 2024-03-11 | A-Award | 0 | 2024-03-13 |
| Lebovits Chaim | officer: President & CEO | 2024-03-11 | A-Award | 0 | 2024-03-13 |
| Lindborg Stacy | officer: Co-Chief Executive Officer | 2023-09-01 | P-Purchase | 1.7741 | 2023-09-05 |
| Lindborg Stacy | officer: Co-Chief Executive Officer | 2023-08-02 | A-Award | 0 | 2023-08-07 |
| Lebovits Chaim | officer: President & CEO | 2023-08-02 | A-Award | 0 | 2023-08-04 |
| Naor Nir | director | 2023-06-19 | A-Award | 0 | 2023-06-21 |
| Naor Nir | director: | 2023-06-19 | 0 | 2023-06-21 | |
| Taylor Kirk | officer: Chief Medical Officer | 2023-05-01 | A-Award | 2.99 | 2023-05-01 |
| Taylor Kirk | officer: Chief Medical Officer | 2023-05-01 | A-Award | 0 | 2023-05-01 |
| Taylor Kirk | officer | 2023-05-01 | 0 | 2023-05-01 | |
| Lebovits Chaim | officer: President & Co-CEO | 2023-04-20 | A-Award | 0 | 2023-04-24 |
| Lindborg Stacy | officer: Co-Chief Executive Officer | 2023-04-20 | A-Award | 0 | 2023-04-24 |
| Lindborg Stacy | officer: Co-Chief Executive Officer | 2022-12-07 | A-Award | 0 | 2023-01-04 |
| Lebovits Chaim | officer: Chief Executive Officer | 2022-09-18 | A-Award | 0 | 2023-01-04 |
| FRENKEL JACOB A | director: | 2022-04-06 | A-Award | 0 | 2022-04-08 |
| Kern Ralph Dr. | officer: COO and Chief Medical Officer | 2022-03-06 | A-Award | 0 | 2022-03-14 |
| Polverino Anthony J. | director | 2022-02-01 | A-Award | 0 | 2022-02-03 |
| TAUB MALCOLM S | director | 2021-12-15 | A-Award | 0 | 2021-12-17 |
| Polverino Anthony J. | director | 2021-12-15 | A-Award | 0 | 2021-12-17 |
| Almenoff June Sherie | director | 2021-12-15 | A-Award | 0 | 2021-12-17 |
| Yablonka Uri | director | 2021-12-15 | A-Award | 0.75 | 2021-12-17 |
| ARBEL IRIT | director | 2021-12-15 | A-Award | 0.75 | 2021-12-17 |
| Kern Ralph Dr. | officer: COO and Chief Medical Officer | 2021-12-10 | A-Award | 0 | 2021-12-10 |
| Lebovits Chaim | officer: Chief Executive Officer | 2021-12-10 | A-Award | 0 | 2021-12-10 |
| TAUB MALCOLM S | director | 2021-12-10 | A-Award | 0 | 2021-12-10 |
| Polverino Anthony J. | director | 2021-12-10 | A-Award | 0 | 2021-12-10 |
| Polverino Anthony J. | director | 2021-12-10 | A-Award | 0 | 2021-12-10 |
| ARBEL IRIT | director | 2021-12-10 | A-Award | 0.75 | 2021-12-10 |
| FRENKEL JACOB A | director | 2021-12-10 | A-Award | 0.75 | 2021-12-10 |
| Abbhi Sankesh | director | 2021-12-10 | A-Award | 0 | 2021-12-10 |
| Yablonka Uri | director | 2021-12-10 | A-Award | 0.75 | 2021-12-10 |
| Almenoff June Sherie | director | 2021-12-10 | A-Award | 0 | 2021-12-10 |
| Bairu Menghisteab | director: | 2021-10-28 | 0 | 2021-11-04 | |
| Patlis Alla | officer: See Remarks | 2021-08-25 | 2.7 | 2021-09-02 | |
| Patlis Alla | officer: See Remarks | 2021-08-25 | 9.51 | 2021-09-02 | |
| Shah Preetam | officer: EVP, CFO and Treasurer | 2020-12-30 | F-InKind | 4.64 | 2020-12-31 |
| Lindborg Stacy | officer: EVP, Head Global Clin Research | 2020-11-17 | P-Purchase | 10 | 2020-11-19 |
| Waclawski Anthony | officer: See Remarks | 2020-09-08 | A-Award | 12.58 | 2020-09-10 |
| Waclawski Anthony | officer: See Remarks | 2020-09-08 | A-Award | 0 | 2020-09-10 |